However, new options have recently become available for treating patients with HR-positive breast cancer—supplementing endocrine therapy with either the mammalian target of rapamycin (mTOR) inhibitor everolimus (Afinitor) or the reversible cyclin-dependent kinase (CDK) 4/6 inhibitor palbociclib (Ibrance). Here, MTOR is linked to breast cancer.